ARMATA PHARMACEUTICALS, INC. Finite-Lived Intangible Assets, Net
ARMATA PHARMACEUTICALS, INC. (ARMP) had Finite-Lived Intangible Assets, Net of $238.00 thousand as of 2019-03-31, per its 10-Q filed 2019-05-06.
Discontinued › Balance Sheet › Assets › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2019-05-06
- 2019-03-31: Finite-Lived Intangible Assets, Net $238.00K.
- 2018-12-31: Finite-Lived Intangible Assets, Net $245.00K.
- 2018-09-30: Finite-Lived Intangible Assets, Net $253.00K.
- 2018-06-30: Finite-Lived Intangible Assets, Net $261.00K.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2019-03-31 | $238.00K 10-Q · filed 2019-05-06 |
| 2018-12-31 | $245.00K 10-Q · filed 2019-05-06 |
| 2018-09-30 | $253.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $261.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $268.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $276.00K 10-K · filed 2019-03-25 |
| 2017-09-30 | $284.00K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $292.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $299.00K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $307.00K 10-K · filed 2018-03-14 |
| 2016-09-30 | $315.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $323.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $330.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $338.00K 10-K · filed 2017-03-27 |
| 2015-09-30 | $346.00K 10-Q · filed 2015-11-16 |
| 2015-06-30 | $354.00K 10-Q · filed 2015-08-13 |
| 2014-12-31 | $369.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |